Shanghai Bovax Biotechnology

Shanghai Bovax Biotechnology develops recombinant protein vaccines and drugs, with quadrivalent, 9-valent and 15-valent HPV vaccine candidates and a recombinant enterovirus 71 vaccine in clinical development. It runs research in Shanghai and a vaccine manufacturing base in Chongqing through its subsidiary Chongqing Bovax Biopharmaceutical. On ClinicalTrials.gov it is the lead sponsor of 4 trials recorded in OnCo (3 in phase 3 or 2/3): NCT06465914 (phase 3, A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent H...), NCT04422366 (phase 3, Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in...), NCT05027776 (phase 3, Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subject...) and NCT06756269 (phase 2, To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chine...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.